About Bayer Animal Health
Since 1919, Bayer Animal Health has been a global leader in promoting the health and well-being of animals, as well as supporting the farmers, veterinarians and pet owners who care for them, through innovative research, therapies and solutions. Today, with more than 100 different animal health and care products in more than 120 countries, Bayer Animal Health is among the world's largest suppliers of veterinary medicines. To further expand our knowledge, we invest about ten percent of our sales into research and development related activities.
Our R&D efforts are currently focusing on the development of new products for livestock and companion animals. In particular, we concentrate on parasiticides, medicines for the treatment of non-infectious diseases, antibiotics as well as non-antibiotic treatment alternatives. We are committed to finding solutions for current challenges as well as anticipating future problems in the area of animal health. Our products are an expression of our dedication to, and respect for, animals, people and environmental sustainability.
About Boehringer Ingelheim Animal Health
On January 1st, 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. For more information, please visit www.boehringer-ingelheim.com
1 Jul 2016
30 April 2017
1 Jul 2016
1 Jan 2017
15 May 2017
15 Aug 2017